CareDx Financial Ratios
NASDAQ: CDNAHealth CareMedical SpecialitiesUSD
63.67+1.47 (+2.36%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
CareDx ratio analysis
CareDx earned a net margin of -5.6% in FY 2025, down from 15.7% a year earlier. Return on equity reached -7.0%, meaning CareDx generated -0.07 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
CareDx financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | 24.01 | — | — | — | — | — | — | — | — |
| Price / sales | 2.69 | 3.53 | 2.30 | 1.89 | 8.02 | 17.52 | 6.81 | 11.60 | 3.54 | 1.10 |
| Price / book | 3.36 | 3.11 | 2.47 | 1.41 | 5.10 | 12.13 | 8.75 | 9.26 | — | 2.29 |
| Gross margin | — | — | — | — | — | — | 64.2% | 56.9% | 55.8% | 74.8% |
| Operating margin | -8.1% | 12.2% | -72.5% | -24.0% | -10.0% | -11.7% | -19.3% | -20.3% | -42.0% | -91.9% |
| Net margin | -5.6% | 15.7% | -67.9% | -23.8% | -10.3% | -9.7% | -17.3% | -61.1% | -114.8% | -97.1% |
| Free cash flow margin | 11.1% | 11.4% | -6.6% | -7.8% | -6.5% | 17.4% | -2.2% | -7.9% | -30.0% | -42.0% |
| Return on equity (ROE) | -7.0% | 13.9% | -72.8% | -17.8% | -6.6% | -6.7% | -22.2% | -48.7% | — | -202.6% |
| Return on assets (ROA) | -5.2% | 10.7% | -40.8% | -14.1% | -5.4% | -5.1% | -14.5% | -35.8% | -66.4% | -51.4% |
| Debt / equity | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | 1.23 |
| Current ratio | 2.86 | 3.94 | 4.02 | 5.10 | 5.61 | 3.95 | 2.07 | 4.16 | 0.62 | 0.65 |
| Revenue growth | 13.8% | 19.1% | -12.9% | 8.6% | 54.2% | 51.3% | 66.0% | 58.4% | 18.9% | 44.4% |
| EPS growth | -143.0% | — | — | — | — | — | — | — | — | — |